Clinical Edit Criteria Proposal

Drug/Drug Class:	**CAR T Cell Therapy Clinical Edit** **Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel)**
Date:	**June 21, 2018**
Prepared for:	**MO HealthNet**
Prepared by:	**MO HealthNet**

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:

To establish MO HealthNet (MHD) Program policy regarding authorization of CAR T Cell Therapy for Kymriah® (tisagenlecleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse in patients up to 25 years of age and for adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma and for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

CAR T Cell Therapy is a type of treatment where the patient's T Cells are modified in a laboratory by adding a chimeric antigen receptor gene, known as CAR. The modified T cells are then infused back into the patient where the T cells target the specific cancer.

Why was this Issue Selected:

Each manufacturer certifies the facilities where CAR T cell therapy is used. MO HealthNet is treating this procedure the same way we do stem cell transplants. MO HealthNet requires all transplants to be done on an in-patient basis. Each request for CAR T Cell therapy is reviewed on a case by case basis to determine the appropriateness of treatment and a contract is put into place between MHD and the facility. This contract specifies among other things the reimbursement for the drug and for the hospital stay. This is a one-time treatment.

All requests for therapy will be reviewed by a Clinical Consultant.

Program-specific information:	**Drug**	**Cost Information**
	• Kymriah® (tisagenlecleucel)	**$ 479,750 MAC** Includes harvesting of cells
	• Yescarta® (axicabtagene ciloleucel)	**$ 373,000 MAC** does not include harvesting of cells
Setting & Population:	MHD participants with the appropriate diagnosis and required previous treatment according to the FDA approved prescribing information	
Type of Criteria:	☐ **Increased risk of ADE**	☐ **Non-Preferred Agent**
	☒ **Appropriate Indications**	☐ **Dose Optimization**
Data Sources:	☐ **Only administrative databases**	☒ **Databases + Prescriber-supplied**

Setting & Population

- Drug for review: Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel)
- Age range: Kymriah® - up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse diagnosis and adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma; Yescarta® - Adult patients
- Gender: Male and female

Black Box Warning

- Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving Kymriah® and Yescarta®. Do not administer Kymriah® or Yescarta® to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids
- Neurological toxicities, which may be severe or life-threatening, can occur following treatment with Kymriah® and Yescarta®, including concurrently with CRS. Monitor for neurological events after treatment with Kymriah® and Yescarta®. Provide supportive care as needed.

Approval Criteria

- Appropriate diagnosis:
  - Kymriah® – Relapsed or Refractory (r/r) B-cell Acute Lymphoblastic leukemia (ALL) that is refractory or in second or later relapse or
  - Kymriah® – Relapsed or Refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell

lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
    - Yescarta® – Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma **AND**

- Documentation of two previously tried lines of systemic therapy
- No Previous CAR T Cell Therapy

Denial Criteria

- Lack of approval criteria
- Previous CAR T Cell Therapy

Required Documentation

Laboratory results:	X	Progress notes:	X
MedWatch form:		Other:	X

References

1. Kymriah® [prescribing information]. East Hanover, NJ. Novartis Pharmaceuticals Corporation May 2018.
2. Yescarta® [prescribing information]. Santa Monica, CA. Kite Pharma, Inc. October 2017.
3. Axicabtagene ciloleucel (Yescarta®) New Drug Update. Magellan Rx Management, November 2017.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2018.
5. USPDI, Micromedex; 2018.
6. Facts and Comparisons eAnswers (online); 2018 Clinical Drug Information, LLC. Last accessed June 8, 2018.